At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
News
An experimental nerve-protecting therapy called RT1999 (smilagenin) will soon be tested in people with amyotrophic lateral sclerosis (ALS) as part of a U.K. platform trial designed to quickly screen potential ALS treatments. The study, called EXPERTS-ALS, is testing several experimental ALS therapies…
People with amyotrophic lateral sclerosis (ALS) who were exposed to smoke from wildfires prior to developing the disease are more than twice as likely to experience respiratory failure or death, according to a new analysis. The findings underscore the need for further research to understand how air pollution and…
The ALS Network will continue to host its ASK ME webinar series throughout 2026, featuring expert-led sessions on advocacy, care, research, and daily life with amyotrophic lateral sclerosis (ALS). This…
A specific alteration in the TDP-43 protein can reduce the viability of nerve cells in a lab model of amyotrophic lateral sclerosis (ALS), causing problems with energy generation and molecular transport within the cell, a new study finds. Notably, however, researchers found that this mutation does not cause TDP-43 protein…
Scientists have developed a way to deliver a nerve-protecting substance past the brain’s natural defenses using fat-based ‘bubbles,’ a strategy that significantly extended survival and preserved movement in mouse models of amyotrophic lateral sclerosis (ALS). This approach, called talineuren, successfully delivered the protective molecule GM1 directly to damaged motor…
Dosing has begun in a new arm of the HEALEY ALS platform trial, with Regimen I — the ninth — testing NUZ-001, an oral small molecule developed by Neurizon Therapeutics to slow declines in function and extend survival in people with amyotrophic lateral sclerosis (ALS). As a platform…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
Blood levels of lactate — a molecule involved in how the body produces energy — may help predict survival and short-term weight changes in people with amyotrophic lateral sclerosis (ALS), according to a new study from Australia and Japan. Researchers found that patients with lower blood lactate levels had…
AB Science has identified a new blood biomarker, produced by certain immune cells, that may help assess the activity of its experimental therapy masitinib in people with amyotrophic lateral sclerosis (ALS). The biomarker, which the company did not disclose for patent protection reasons, is capable of identifying patients…
Recent Posts
- Holding the line: Why I’d keep my ALS progression exactly as it is
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- MDA 2026: New ALS platform trial adds RT1999 to speed search for treatments
- Making ALS Advocacy My Purpose
- MDA 2026: Wildfire smoke exposure raises risks for ALS patients